MOLECULAR MEDICINE REPORTS 12: 3115-3120, 2015
X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo JI LI1,2*, KONGBO ZHAO3*, FU WANG4, JINFANG CAI2, ZONGYU LI2 and LIN ZOU2 1
Department of Orthopedics, The Quanzhou Licheng Xingxian Hospital, Quanzhou 362005; 2Department of Orthopedics, The Jinan Military General Hospital, Jinan 250031; 3Department of Orthopedics, Linyi People's Hospital, Linyi 276000; 4 Department of Orthopedics, Shandong Provincial Hospital, Jinan 250021, P.R. China Received July 26, 2014; Accepted April 10, 2015 DOI: 10.3892/mmr.2015.3729
Abstract. Manassantin A has been well-established as an inhibitor of HIF-1. In the present study, a new manasantin A derivative, X609, with decreased stereochemical complexity, rendering it amenable to a simplified synthesis scheme, was synthesized and was found to increase HIF‑1 inhibitory activity. X609 exhibited antiproliferative activity in a broad spectrum of tumor cell lines, via HIF‑1‑dependent mechanisms. X609 may induce apoptosis in MG‑63 cells through activation of the mitochondrial pathway. Oral administration of X609 significantly inhibited the growth of human osteosarcomas implanted into nude mice. In light of the results of the present study, it may be possible to develop X609 for use as a novel antitumor agent, which targets human osteosarcoma. Introduction Osteosarcoma (OS), which has a poor prognosis in children and adolescents, is the most common primary malignant bone tumor, and predominantly occurs in the metaphyses of long bones (1). Although the application of adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate in the treatment of OS has significantly improved the survival of patients with this disease, there are difficulties with the use of this treatment, including severe side effects and the development of chemoresistance (2,3). The overall 5‑year survival rate is ~65%, while the rates following recurrence or metastasis are
X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo JI LI1,2*, KONGBO ZHAO3*, FU WANG4, JINFANG CAI2, ZONGYU LI2 and LIN ZOU2 1
Department of Orthopedics, The Quanzhou Licheng Xingxian Hospital, Quanzhou 362005; 2Department of Orthopedics, The Jinan Military General Hospital, Jinan 250031; 3Department of Orthopedics, Linyi People's Hospital, Linyi 276000; 4 Department of Orthopedics, Shandong Provincial Hospital, Jinan 250021, P.R. China Received July 26, 2014; Accepted April 10, 2015 DOI: 10.3892/mmr.2015.3729
Abstract. Manassantin A has been well-established as an inhibitor of HIF-1. In the present study, a new manasantin A derivative, X609, with decreased stereochemical complexity, rendering it amenable to a simplified synthesis scheme, was synthesized and was found to increase HIF‑1 inhibitory activity. X609 exhibited antiproliferative activity in a broad spectrum of tumor cell lines, via HIF‑1‑dependent mechanisms. X609 may induce apoptosis in MG‑63 cells through activation of the mitochondrial pathway. Oral administration of X609 significantly inhibited the growth of human osteosarcomas implanted into nude mice. In light of the results of the present study, it may be possible to develop X609 for use as a novel antitumor agent, which targets human osteosarcoma. Introduction Osteosarcoma (OS), which has a poor prognosis in children and adolescents, is the most common primary malignant bone tumor, and predominantly occurs in the metaphyses of long bones (1). Although the application of adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate in the treatment of OS has significantly improved the survival of patients with this disease, there are difficulties with the use of this treatment, including severe side effects and the development of chemoresistance (2,3). The overall 5‑year survival rate is ~65%, while the rates following recurrence or metastasis are
